News | Microbion News | Microbion


Microbion Announcements

Feb 22 2021
Microbion Corporation Receives Additional Funding Support from the Cystic Fibrosis Foundation to Speed Advancement of Inhaled Pravibismane
Jan 12 2021
5N Plus Acquires Stake in Microbion and Secures Drug Substance Manufacturing Rights
May 28 2020
Microbion Awarded up to $17.1 Million from CARB-X and the Cystic Fibrosis Foundation to Develop Inhaled Antimicrobial for Chronic Respiratory Infections in CF
May 27 2020
Microbion Corporation Announces Orphan Drug Designation Granted for Pravibismane Suspension for Inhalation by US FDA
May 04 2020
Microbion Corporation Announces Litigation Settlement Agreement, Including a License Agreement, with NYU Langone Health
Oct 28 2019
Microbion Corporation Announces Results from Randomized, Double Blind, Placebo-Controlled Phase 1b Trial of Pravibismane (MBN-101) for Treatment of Moderate to Severe Chronic Infected Diabetic Foot Ulcers
Oct 25 2019
Microbion Corporation Announces Generic Name for Lead Antimicrobial Compound: Pravibismane
Apr 15 2019
Microbion Corporation to Present Data Highlighting Broad Spectrum Activity of BisEDT at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Jan 04 2017
Quark Venture & GF Securities Invest US$25M in Microbion to Advance New Class of Drugs
Aug 03 2016
MBN-101 Received FDA Fast Track Designation: Adjunctive Treatment of Diabetic Foot Ulcer Infections
Jun 15 2016
Microbion Corporation Announces First Patient Treated in Phase 2a Orthopedic Infection Trial
May 25 2016
MBN-101 Received FDA QIDP Designation for Adjunctive Treatment of Moderate & Severe DFI

Microbion in the News